Authors

Latest:

Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Peter Schmid, FRCP, MD, PhD

Latest:

Schmid Summarizes Updates in HER2-Positive Breast Cancer Management

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Mylin A. Torres, MD

Latest:

Dr Torres on Treatment With ADCs in Breast Cancer

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Alessandro Gronchi, MD

Latest:

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Daniel Keifenheim, PhD

Latest:

Novel Tubulin-Targeting Therapies Make Headway

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

Tim Cortese

Latest:

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

Kent Hoskins, MD

Latest:

Dr. Hoskins on the Impact of Race on Breast Cancer Outcomes

Kent Hoskins, MD, discusses the impact of race on breast cancer outcomes.

Emily C. Ayers, MD

Latest:

Dr. Ayers on the Evolving Treatment Landscape in CLL

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

Caron A. Jacobson, MD, MMSc

Latest:

Overcoming Barriers and Improving CAR T Care in Academic and Community Settings

Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.

Eleonora Dondossola, PhD

Latest:

Dr Dondossola on the Importance of Studying Bone Metastasis in RCC

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

Brian C. Grieb, MD, PhD

Latest:

Dr Grieb on the Need for Novel Biomarkers in CRC

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Jeffrey Laurence, MD, Weill Cornell Medicine

Latest:

Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

John P. Sfakianos, MD

Latest:

Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Aatur D. Singhi, MD, PhD

Latest:

Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

Asim V. Farooq, MD, University of Chicago Medical Center

Latest:

Influencing Factors to Initially Targeting BCMA in MM

Geoffrey Shouse, DO, PhD

Latest:

Dr Shouse on the Importance of NGS Testing in Follicular Lymphoma

Geoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.

Lacey J. Padrón, PhD

Latest:

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Matthew J. Ehrhardt, MD, MS

Latest:

Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

Eduardo Santos, MD, FACP, FCCP

Latest:

Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLC

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Sarah Lang, MD, MBA

Latest:

Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial Cancer

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.